PRODUCT: CUDC-907

ALTERNATE NAMES: CUDC907; CUDC 907; N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide

CATALOG#: B1675-5, -25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: $C_{23}H_{24}N_8O_4S$

MOLECULAR WEIGHT: 508.55

CAS NUMBER: 1339928-25-4

APPEARANCE: Solid powder

SOLUBILITY: DMSO

PURITY: >98%

STORAGE: Dry, dark and at 4℃ for short term (days to weeks) or at -20℃ for long term. Protect from air and light.

DESCRIPTION: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Qian C et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res 2012, 18(15):4104-4113.
2. Wong KK et al. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010, 20(1):87-90.
3. Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9(8):550-562.
4. Kim HJ et al. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011, 3(2):166-179.

RELATED PRODUCTS:

- BEZ235 (NVP-BEZ235) (Cat. No. 1626-5, 25)
- GDC-0941 bismesylate (Cat. No. 1623-1, 5)
- Deforolimus (Cat. No. 1587-5, 25)
- IC87114 (Cat. No. 1661-1)
- LY 294002 (Cat. No. 1667-5, 25)
- mTOR Inhibitor, Ku-0063794 (Cat. No. 1779-1, 5)
- PI-103 (Cat. No. 1728-1, 5)
- PP242 (Cat. No. 1658-1)
- Rapamycin (Cat. No. 1568-5, 50)
- Temsirolimus (Cat. No. 1600-5, 25)
- TGX-115 (Cat. No. 1660-1)
- TGX-221 (Cat. No. 1781-1, 5)
- Wortmannin (Cat. No. 1670-1)

USAGE: ***FOR RESEARCH USE ONLY! Not to be used in humans***

BioVision Incorporated
155 S. Milpitas Boulevard, Milpitas, CA 95035 USA

Tel: 408-493-1800 | Fax: 408-493-1801
www.biovision.com | tech@biovision.com